Alvotech (ALVOW)
1.11
0.05 (4.72%)
At close: Apr 17, 2025, 9:30 AM
1.11
0.00%
After-hours: Apr 16, 2025, 04:00 PM EDT
Company Description
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets.
The company is based in Iceland.
Alvotech
| Country | IS |
| IPO Date | Jun 16, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,012 |
| CEO | Robert Wessman |
Contact Details
Address: Saemundargata 15-19 Reykjavik, IS | |
| Website | https://www.alvotech.com |
Stock Details
| Ticker Symbol | ALVOW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001898416 |
| CUSIP Number | L01800116 |
| ISIN Number | LU2458333858 |
| Employer ID | 98-1629342 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Robert Wessman | Chief Executive Officer, Founder & Executive Chairman |
| Faysal Kalmoua | Chief Operating Officer & Director |
| Joel Morales | Chief Financial Officer |
| Anil Okay | Chief Commercial Officer |
| Anthony M. Maffia III | Chief Regulatory Affairs Officer |
| Benedikt Stefansson | Vice President of Investor Relations and Global Communications |
| Giedrius Zunda | Chief Technical Officer |
| Jenny Sif Steingrimsdottir | Vice President of People & Culture |
| Joseph E. McClellan | Chief Scientific Officer |
| Tanya Zharov | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 6-K | Filing |
| Mar 27, 2025 | 20-F | Filing |
| Mar 27, 2025 | 6-K | Filing |
| Mar 26, 2025 | 6-K | Filing |
| Mar 20, 2025 | 6-K | Filing |
| Mar 18, 2025 | 6-K | Filing |
| Feb 24, 2025 | 6-K | Filing |
| Feb 18, 2025 | 6-K | Filing |
| Jan 27, 2025 | 6-K | Filing |
| Dec 23, 2024 | 6-K | Filing |